Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 9/20 | 0.61 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.49 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | F9 | P00740 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | F11 | P03951 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10029168 | 1.00 | CHEK2 (0.61) | CHEK2CSNK1DCSNK1EMAPK14NPBWR1 | |
| SCHEMBL17393280 | 0.92 | CHEK2 (0.57) | CHEK2CSNK1DCSNK1EMAPK14NPC1 | |
| SCHEMBL17393277 | 0.92 | CHEK2 (0.57) | CHEK2CSNK1DCSNK1EMAPK14NPC1 | |
| SCHEMBL10029167 | 0.87 | CHEK2 (0.60) | CHEK2NPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL1841112 | 0.87 | CHEK2 (0.60) | CHEK2NPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL7976836 | 0.83 | F10 (0.54) | CHEK2CSNK1DCSNK1EMAPK14MAPK1 | |
| SCHEMBL28028783 | 0.82 | CHEK2 (0.60) | CHEK2MEN1KMT2A | |
| SCHEMBL17393379 | 0.82 | CHEK2 (0.56) | CHEK2MEN1NPC1ALDH1A1MAPT | |
| SCHEMBL17393611 | 0.82 | CHEK2 (0.56) | CHEK2MEN1NPC1ALDH1A1MAPT | |
| SCHEMBL17393422 | 0.81 | CHEK2 (0.57) | CHEK2MEN1NPC1ALDH1A1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168665-B2 | Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2012-05-01 | — | — | US | claimed |
| EP-2079709-B1 | SUBSTITUTED 2-PHENYL-BENZIMIDAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS (FR) | 2011-05-18 | — | — | EP | claimed |
| US-20090239915-A1 | Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2009-09-24 | — | — | US | claimed |
| EP-2079709-A1 | SUBSTITUTED 2-PHENYL-BENZIMIDAZOLES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-07-22 | — | — | EP | claimed |
| WO-2008037381-A1 | SUBSTITUTED 2-PHENYL-BENZIMIDAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-04-03 | — | — | WO | claimed |
| EP-1905764-A1 | Substituted 2-Phenyl-benzimidazoles and their use as pharmaceuticals | Sanofi-Aventis (FR) | 2008-04-02 | — | — | EP | claimed |
| US-8168665-B2 | Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2012-05-01 | — | — | US | disclosed |
| EP-2079709-B1 | SUBSTITUTED 2-PHENYL-BENZIMIDAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS (FR) | 2011-05-18 | — | — | EP | disclosed |
| US-20090239915-A1 | Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2009-09-24 | — | — | US | disclosed |
| EP-2079709-A1 | SUBSTITUTED 2-PHENYL-BENZIMIDAZOLES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008037381-A1 | SUBSTITUTED 2-PHENYL-BENZIMIDAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-04-03 | — | — | WO | disclosed |
| EP-1905764-A1 | Substituted 2-Phenyl-benzimidazoles and their use as pharmaceuticals | Sanofi-Aventis (FR) | 2008-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239915-A1 | Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals | NOS2, NOS3, NOS1 | CHEK2 4134/4885CSNK1D 774/4885CSNK1E 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.